Discover
MDGL
Madrigal Pharmaceuticals, Inc.
514.39
6 x 529.00
1 x 530.50
bid
ask
-
22.56
4.20%
4 @ 04:00 PM
510.38 -4.01 (0.78%)
| Ytd | -11.67% | |
| 1y | 71.37% |
512.75
day range
542.97
284.02
52 week range
615.00
| Open | 539.67 | Prev Close | 536.95 | Low | 512.75 | High | 542.97 | Mkt Cap | 11.86B |
| Vol | 303.74K | Avg Vol | 328.33K | EPS | -13.48 | P/E | N/A | Forward P/E | 41.55 |
| Beta | -1.06 | Short Ratio | 14.11 | Inst. Own | 106.48% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 508.68 | 200-d Avg | 496.57 | 1yr Est | 678.71 |
| Income Statement | |||
| Total Revenue | 311.34M | ||
| Revenues (USD) | 311.34M | ||
| Cost of Revenue | 26.85M | ||
| Gross Profit | 284.49M | ||
| Operating Expenses | 377.21M | ||
| Research and Development Expense | 108.69M | ||
| Selling, General and Administrative Expense | 268.52M | ||
| Operating Income | -92.72M | ||
| Interest Expense | 7.82M | ||
| Net Income | -94.39M | ||
| Net Income Common Stock | -94.39M | ||
| Net Income Common Stock (USD) | -94.39M | ||
| Consolidated Income | -94.39M | ||
| Earnings per Basic Share | -3.25 | ||
| Earnings per Basic Share (USD) | -3.25 | ||
| Earnings per Diluted Share | -3.25 | ||
| Earning Before Interest & Taxes (EBIT) | -86.57M | ||
| Earning Before Interest & Taxes (USD) | -86.57M | ||
| Weighted Average Shares | 29.03M | ||
| Weighted Average Shares Diluted | 29.03M | ||
| Balance Sheet | |||
| Cash and Equivalents | 232.19M | ||
| Cash and Equivalents (USD) | 232.19M | ||
| Investments | 585.74M | ||
| Investments Current | 585.74M | ||
| Trade and Non-Trade Receivables | 187.36M | ||
| Current Assets | 1.18B | ||
| Property, Plant & Equipment Net | 14.24M | ||
| Total Assets | 1.23B | ||
| Debt Current | 1.70M | ||
| Total Debt | 347.31M | ||
| Current Liabilities | 338.26M | ||
| Debt Non-Current | 345.61M | ||
| Total Liabilities | 683.87M | ||
| Accumulated Retained Earnings (Deficit) | -2.18B | ||
| Accumulated Other Comprehensive Income | 1.08M | ||
| Shareholders Equity | 543.45M | ||
| Shareholders Equity (USD) | 543.45M | ||
| Assets Non-Current | 45.02M | ||
| Total Debt (USD) | 347.31M | ||
| Goodwill and Intangible Assets | 7.28M | ||
| Inventory | 112.07M | ||
| Liabilities Non-Current | 345.61M | ||
| Trade and Non-Trade Payables | 60.80M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 794.00K | ||
| Net Cash Flow from Financing | 2.33M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 28.41M | ||
| Capital Expenditure | -3.85M | ||
| Issuance (Purchase) of Equity Shares | 2.33M | ||
| Net Cash Flow from Investing | 192.19M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 196.04M | ||
| Net Cash Flow from Operations | -167.43M | ||
| Effect of Exchange Rate Changes on Cash | 1.32M | ||
| Share Based Compensation | 34.02M | ||